Medicinal cannabis cultivation and manufacture update John Skerritt Deputy Secretary for Health Products Regulation Commonwealth Department of Health Brisbane, Thursday 13 July 2017
Today’s program (discussion time after each item) 10.00 - 10.15 Welcome and purpose of the meeting John Skerritt, Commonwealth Department of Health 10.15 - 11.15 Developments on cultivation and manufacture Thomas Stoddart, Office of Drug Control group discussion 11.15 - 12.00 Quality requirements and standards John Skerritt, Commonwealth Department of Health Quality requirements for manufactured products Quality standards for the raw material (TGO 93) group discussion 12.00 - 12.45 Lunch 1
Manufacturing quality requirements and product standards John Skerritt Deputy Secretary for Health Products Regulation Commonwealth Department of Health Brisbane, Thursday 13 July 2017
“Home made” cannabis extracts are from illegally sourced materials, often of varying strengths and may contain contaminants
Concerns about the quality of medicinal cannabis products … they may be given to immunocompromised patients • Variation in cannabinoid content , in particular of active ingredient(s) • Contamination with pesticides • Microbial contamination • Mycotoxins (aflatoxins and ochratoxin A) • Contaminants arising from the manufacturing process e.g. solvents • Adulteration with synthetic psychoactive compounds • Fortification with synthetic THC • Mis-identification of the plant material • Adulteration with other plant material 4
CBS NEWS February 7, 2017, 11:08 AM Contamin inated m medic ical m al mar arij ijuan ana be belie lieved t to hav ave k kille illed can ancer pat atie ient Is your medical marijuana safe? UC Davis doctors say dangerous bacteria, fungi can lurk in pot www.sacbee.com/news/local/health-and- medicine/article131391629.html#storylink=cpy Health Canada orders medical marijuana growers to test for banned pesticides OTTAWA SUN SATURDAY, MAY 06, 2017 5
Therapeutic Goods Order 93 1. Sets out minimum requirements for the quality of: • medicinal cannabis products • the cannabis plant used in the manufacture of medicinal cannabis products • any ingredient used in the manufacture of medicinal cannabis products 2. Sets out requirements on the manufacturing process for medicinal cannabis products, and applies to: • any medicinal cannabis product imported into, exported from, or supplied in Australia • cannabis plant used in the manufacture of medicinal cannabis products • any other ingredients used in the manufacture of medicinal cannabis products, such as excipients • steps and procedures carried out in the manufacture of medicinal cannabis products 6
TGO 93 incorporates the requirements of the European Pharmacopeia general monograph for Pharmaceutical Preparations (2619) This encompasses the requirements of: • specific monographs of the Ph.Eur. for pharmaceutical raw materials (e.g. active ingredients, excipients) • general texts (e.g. Residual Solvents (5.4)) and • other general monographs of the Pharmacopeia including: - Herbal Drugs (1433) - Herbal Drug Preparations (765) - Herbal Drug Extracts (765) - Substances for Pharmaceutical Use (2034) - dosage form monographs e,g. Oromucosal Preparations (1807) 7
Source of active ingredients and adulterants • The cannabis plant used in the manufacture of medicinal cannabis products must be positively identified using macroscopic and microscopic examination and chromatographic procedures • All active ingredients and cannabinoids in medicinal cannabis products must be manufactured from the cannabis plant only (synthetic cannabinoids are not allowed in “medicinal cannabis”) • Decontamination of cannabis plant material (e.g. by gamma irradiation) is allowed provided it does not affect product quality • The formulated medicine or any of its ingredients must not be adulterated with undeclared substances , although use of an excipient or processing aid in manufacture is permitted 8
Cannabis plant tests Sponsors/manufacturers must ensure that the cannabis plants used to manufacture products meet requirements 1. Aflatoxins (Ph. Eur requirements) 2. Ochratoxin A (< 20 µg/kg) 3. Foreign matter (Ph. Eur requirements < 2 %) 4. Heavy metals (As < 3.0 ppm, Cd < 0.5 ppm, Pb < 5.0 ppm, Hg < 0.5 ppm) 5. Pesticides (Ph. Eur. requirements) 6. Total ash (< 20 %) 9
The acid form dominates in plant material OH OH H H COOH O O THC-acid THC OH OH H H COOH HO HO CBD-acid CBD 10
Assay limits for dosage forms Average content of active ingredient Dosage form (including corresponding acids) (% stated content) Herbal final form 80.0 - 120.0 Tablets and capsules 90.0 - 110.0 (unregistered) Other dosage forms 90.0 - 110.0 Any suitably validated test method can be used. Examples include : • Monograph Cannabis Flos Version 7.1 (Nov 28, 2014) 40953, Dutch Office of Medicinal Cannabis Recommended methods for the identification and analysis of cannabis and • cannabis products United Nations Office on Drugs and Crime. 11
GMP requirements • Domestically manufactured APIs are subject to both current GMP and TGO93 • For manufactured products planned for SAS/ Authorised Prescriber pathways, the currently PIC/S Guide to GMP applies • For clinical trial products , Annex 13 of the Code is important 12
GMP for medicinal cannabis APIs The API is the active ingredient that is the starting material for the manufacturing process of the finished product. For medicinal cannabis, the API could be: • An extracted/ purified cannabinoid from the cannabis plant • An extract of specified parts or powdered parts of the cannabis plant 13
Medicinal cannabis API manufacture (TGO 93 also applies to APIs) Type of The Code of GMP (Part II) manufacturing is applied to processes highlighted in red API extracted Collection of Cutting/initial Introduce the Isolate and Process plants extraction(s) purify and pack API starting (plant) material Herbal extracts Collection of Cutting/initial Further Process plants extraction(s) extract and pack (used as API) API powdered Collection of Cutting and Process commuting and pack herbs plants and/or cultivation and harvesting 14
GMP requirements for domestically- manufactured products for clinical trials Annex 13 of the PICS Guide applies. Key points: • Quality Management system • Receiving/storage/usage/security (S8 requirements) • Personnel/training • Premises/Equipment • Manufacturing: Operation/Critical parameters • Packaging: operation/packaging materials/labelling/expiry/ blinding operation 15
GMP requirements for domestically- manufactured products to be provided through SAS/ Authorised Prescriber pathways • The finished medicinal cannabis product is the dosage form in which the medicinal cannabis is intended to be administered to the patient , e.g. oil, tincture, extract, capsule, tablet etc • The domestic manufacture of the finished medicinal cannabis product is required to be in compliance with – Code of GMP, relevant Annexes – Relevant product standards - TGO 77 (Microbiological), and TGO 93 (Medicinal Cannabis) 16
Termed “approved access” in the Guidance …. • Quality control/verification , effectiveness of blinding • Review/assessment/ release of batches • Shipping /security codes/storage conditions • Complaints /recalls/returns/destructions • Documentation : specifications/methods/in-process • Approved labelling/clinical trials protocols/technical agreements/stability/storage records/manufacturing and packaging instructions and records • Supplier qualification: – Understanding the nature of the starting material – Approval of starting material suppliers/specifications – Reduced sampling and testing considerations – Periodic review 17
Domestic product GMP: Process validation • Any risk based approach should be consistent with Annex 20 of current GMP Code – Prior to validation, all requirements of equipment qualification and validation of test methods should have been appropriately completed – Concurrent or prospective validation would normally be expected for new dosage forms/processes – Product Grouping validation should be based on scientific justification which may be difficult to achieve for medicinal cannabis, so each dosage form and batch size should be validated 18
Domestic product GMP: Testing • Testing requirements in process validation studies should consider the physical characteristics of a particular ingredient to ensure homogeneity/strength are addressed • Successful validation would ensure that all critical process parameters are assessed as consistently controlled and typically covers extraction, concentration, drying, mixing into the dosage form, and packaging into finished product • Release of a batch used for a Process Validation is acceptable if the batch meets release specifications 19
Recommend
More recommend
